A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study)
Adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab, or adding SCIB1 to pembrolizumab, may improve outcomes in advanced melanoma.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies